Hims & Hers Introduces Weight Loss Programme and Hers Platform in the UK

Hims & Hers has expanded its services in the UK with the launch of its Weight Loss Programme and the introduction of the Hers platform designed specifically for women. The digital health company now offers eligible customers access to personalised weight management care supported by GMC-registered clinicians. Following an intake assessment, clinicians evaluate each individual’s medical history, suitability for treatment and potential contraindications before confirming a care plan. Treatment pathways may include branded GLP-1 options such as Mounjaro or Wegovy, as well as the oral non-prescription medicine Orlos.

The programme incorporates continuous access to a care team and educational resources aimed at supporting changes in nutrition, activity and sleep habits. The approach is structured to promote long-term health outcomes rather than short-term weight reduction, and customers receive ongoing guidance from licensed clinicians through scheduled follow-ups and asynchronous messaging. Adjustments to treatment plans can be made as needed, with continued access to GMC-registered doctors.

David Meinertz, GM International at Hims & Hers, said: “The launch of Hims & Hers’ comprehensive Weight Loss Programme and the vital introduction of the Hers platform, our dedicated platform for women, represents a significant deepening of our commitment to the UK. Our doctor-designed treatment plans will complement the NHS by providing accessible, evidence-based, and sustainable long-term weight management care to those who need it, discreetly and conveniently.”

Craig Primack MD, Head of Weight Loss at Hims & Hers, added: “Obesity is a global epidemic, and the scale of the challenge in the UK requires a comprehensive solution that prioritises long-term health over quick fixes. Bringing our trusted, comprehensive approach to the UK will help people lead fuller and healthier lives. And with the launch of the Hers platform, we are ensuring women have access to the dedicated, personalised care they need.”

The company’s expansion comes amid rising obesity prevalence, with an estimated 64% of UK adults overweight or living with obesity. Access to GLP-1 therapies remains limited across both the NHS and private sector due to demand and cost pressures. Hims & Hers plans to broaden its UK offerings further as interest in personalised, clinician-supported care continues to grow.

Click here for the original news story.